Tamper-proof narcotic delivery system

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 7968119
APP PUB NO 20030026838A1
SERIAL NO

10183678

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

A composition for oral, transdermal or subdermal administration to a subject is described. The composition contains: (a) an agonist component; (b) an antagonist component containing at least one antagonist and having a delayed time of release; and (c) an immediate release antagonist removal component, where the subject includes a gastrointestinal tract and the antagonist removal component is present in an amount sufficient to substantially remove the antagonist component from the gastrointestinal tract of the subject before the time of release of the antagonist component. The composition may be delivered to the subject by a method which includes the step of administering the composition orally, transdermally or subdermally to the subject. When the composition of the present invention is administered orally, the method of the present invention may include the step of administering a potassium compound to the subject.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • Assignment data not available. Check PTO

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Farrell, John J Greenwich, US 14 178

Cited Art Landscape

Patent Info (Count) # Cites Year
 
Other [Check patent profile for assignment information] (4)
5580569 Article for tissue-specific delivery of therapeutic agents 14 1993
5512587 Method for treating opiate withdrawal 1 1994
5811451 Pharmaceutical compositions comprising an opiate antagonist and calcium salts, their use for the treatment of endorphin-mediated pathologies 36 1996
5919473 Methods and devices for delivering opioid analgesics to wounds via a subdermal implant 92 1997
 
MINNESOTA MINING AND MANUFACTURING COMPANY (1)
5698217 Transdermal drug delivery device containing a desiccant 36 1995
 
PHARMACIA & UPJOHN AB (1)
5885486 Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof 25 1996
 
CERTA DOSE, INC. (1)
6132416 Universal medication dosing system 23 1998
 
Societe de Conseils de Recherches et d'Applications (S.C.R.A.S.) (1)
5569467 Process for the preparation of microballs and microballs thus obtained 16 1994
 
ALZA CORPORATION (1)
5540912 Viscous suspensions of controlled-release drug particles 100 1994
 
VALEANT INTERNATIONAL BERMUDA (2)
5518730 Biodegradable controlled release flash flow melt-spun delivery system 231 1992
6013280 Immediate release dosage forms containing microspheres 25 1997
 
SIMON, DAVID LEW (1)
5783583 17-(cyclopropylmethyl)-4,5alpha-epoxy-6-methylenemorphinan-3,14-diol, hydrochloride salt for the purpose of rapid narcotic detoxification 7 1996
 
The Lynx Project Limited (1)
6310072 Production of analgesic synergy by co-administration of sub-analgesic doses of a MU opioid agonist and a kappa-2 opioid agonist 69 1997
 
EURO-CELTIQUE S.A. (1)
6068855 Pharmaceutical composition containing a fusible carrier and method for producing the same 94 1997
 
PURDUE PHARMA L.P. (9)
5958452 Extruded orally administrable opioid formulations 235 1997
6228863 Method of preventing abuse of opioid dosage forms 220 1998
6277384 Opioid agonist/antagonist combinations 139 1998
6231886 Methods of providing sustained treatment with opioids 7 1999
6335033 Melt-extrusion multiparticulates 135 1999
6261599 Melt-extruded orally administrable opioid formulations 185 1999
6375957 Opioid agonist/opioid antagonist/acetaminophen combinations 217 2000
* 6696088 Tamper-resistant oral opioid agonist formulations 169 2001
2002/0058,673 Opioid agonist/opioid antagonist/acetaminophen combinations 52 2001
 
GLYCOBIOSCIENCES INC. (2)
5716631 Long acting narcotic analgesics and antagonists 7 1996
5709883 Long acting narcotic analgesics and antagonists 10 1997
 
DEXCEL PHARMA TECHNOLOGIES LTD. (1)
5840332 Gastrointestinal drug delivery system 118 1996
 
The United States of America as represented by the Department of Health and Human Services (1)
5780589 Ultraselective opioidmimetic peptides and pharmacological and therapeutic uses thereof 19 1994
 
ICN HUNGARY RT. (1)
5317022 Pharmaceutical composition and use 77 1992
 
INTENSIVE NARCOTIC DETOXIFICATION CENTERS OF AMERICA, LLC (1)
5922705 Rapid narcotic detoxification 3 1998
 
FUISZ TECHNOLOGIES LTD. (1)
6020002 Delivery of controlled-release system(s) 16 1997
 
The United States of America as represented by the Secretary of the Army (2)
5834477 Opiate analgesic formulation with improved safety 61 1994
6217911 sustained release non-steroidal, anti-inflammatory and lidocaine PLGA microspheres 38 1996
 
RECKITT BENCKISER HEALTHCARE (UK) LIMITED (1)
4582835 Analgesic compositions 148 1984
 
The Rockefeller University (1)
4987136 Method for controlling gastrointestinal dysmotility 135 1986
 
LUMARA HEALTH IP LTD. (1)
6214379 Maximizing effectiveness of substances used to improve health and well being 28 1999
 
QUADRANT DRUG DELIVERY LIMITED (1)
5958455 Oral solid dosage forms, methods of making same and compositions thereof 36 1996
 
BRISTOL-MYERS SQUIBB COMPANY (1)
4457933 Prevention of analgesic abuse 164 1981
 
Ortho-McNeil Pharmaceutical, Inc. (1)
4906463 Transdermal drug-delivery composition 113 1988
 
EDT PHARMA HOLDINGS (1)
6066339 Oral morphine multiparticulate formulation 38 1997
 
CHILDREN'S MEDICAL CENTER CORPORATION (1)
4391797 Systems for the controlled release of macromolecules 122 1981
 
NAPP PHARMACEUTICAL GROUP LIMITED (1)
6326027 Controlled release formulation 101 1995
 
SS Pharmaceutical Co., Ltd. (1)
5496561 Controlled release-initiation and controlled release-rate pharmaceutical composition 34 1994
 
JANSSEN PHARMACEUTICA NV (1)
5792477 Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent 94 1997
 
BAYLOR UNIVERSITY (1)
5855915 Tablets or biologically acceptable implants for long-term antiinflammatory drug release 16 1996
 
VINCENT C. GIAMPAPA (1)
5494677 Tissue-specific implantable therapeutic agent delivery system 7 1993
 
MYLAN TECHNOLOGIES, INC. (1)
5679373 Process of assembling a transdermal patch incorporating a polymer film incorporated with an active agent 22 1995
 
UNIVERSITY OF CHICAGO, THE (1)
5972954 Use of methylnaltrexone and related compounds 124 1997
 
BAKER HUGHES INCORPORATED (1)
6130258 Polyvalent metal cations in combination with dithiocarbamic acid compositions as board spectrum demulsifiers 1 1998
 
HISAMITSU PHARMACEUTICAL CO., INC. (1)
5820877 Percutaneously administrable patch preparation 10 1996
 
TEVA PHARMACEUTICAL INDUSTRIES LTD. (1)
5609886 Microspheres for the controlled release of water-soluble substances and process for preparing them 15 1995
* Cited By Examiner

Patent Citation Ranking

Forward Cite Landscape

Patent Info (Count) # Cites Year
 
RECRO GAINESVILLE LLC (3)
9132096 Abuse resistant pharmaceutical compositions 1 2014
9486451 Abuse resistant pharmaceutical compositions 0 2015
9452163 Abuse resistant pharmaceutical compositions 0 2015
 
Pharmaceutical Manufacturing Research Services, Inc. (1)
9492444 Extruded extended release abuse deterrent pill 0 2014
 
PURDUE PHARMA L.P. (2)
* 2008/0020,028 TRANSDERMAL DOSAGE FORM COMPRISING AN ACTIVE AGENT AND A SALT AND A FREE-BASE FORM OF AN ADVERSE AGENT 24 2007
* 8758825 Sequestered antagonist formulations 0 2013
* Cited By Examiner

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Dec 28, 2018
11.5 Year Payment $7400.00 $3700.00 $1850.00 Dec 28, 2022
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00